Published: 28. February, 2023
Cessatech today publishes its annual report for the fiscal year 2022, which also includes…
Cessatech today publishes its annual report for the fiscal year 2022, which also includes the fourth quarter of 2022 financial reporting.
During 2022 we made much progress with our clinical development and CMC & Device activities, setting the foundation for a news-rich 2023 year ahead. As well as reporting positive top line results from 0204 and 0206 we began our pivotal study 0205. Recruitment for this study is now well underway and we look forward to announcing data from this study later in 2023.
Comment from the CEO, Jes Trygved
We have two main tasks for 2023 – 1) the finalization of the commercial business setup for Europe and US, and 2) to complete the pivotal clinical study 0205.
We managed to complete most of the tasks we had set up for the year 2022 – including reporting successful outcome of both study 0204 and 0206, conducting the first human factor tests on the nasal device and most importantly initiating the pivotal study 0205 of our lead asset CT001. I am very proud that we managed it all together and this is only due to our great team and collaboration partners. In 2023 it will all come together – hopefully a huge ketchup effect of positive events.